The colony-stimulating factors (CSFs) are glycoproteins integrally involved in producing, differentiating, and activating phagocytic cells. The names of the CSFs were originally assigned according to the major type of phagocyte produced in the CSF bioassay (9, 10) . Four major CSFs have been classified in this system: interleukin 3 (IL-3, or multi-CSF), which induces the formation of granulocytes, macrophages, and eosinophils; granulocyte-macrophage CSF (GM-CSF), which induces the formation of granulocytes and macrophages; macrophage CSF, which induces the formation of macrophages; and granulocyte CSF, which induces the formation of granulocytes.
The CSFs may be important mediators of host defenses against infectious pathogens (2, 8, 11, 13, 21) . The capacity of CSFs to increase the number of available phagocytes is one host defense mechanism aimed at killing invading microorganisms. In addition to increasing phagocyte numbers, CSFs also modulate secretory capacity, chemotaxis, and killing mechanisms of phagocytes. Thus, the CSFs are important regulatory glycoproteins that enhance both the production and function of phagocytes.
Our model of Chlamydia trachomatis pneumonia, caused by the mouse pneumonitis agent (MoPn), has been devel-* Corresponding author. oped to investigate host defenses against infectious challenge (14) (15) (16) (17) (18) (19) . In this model, we have used both athymic (nulnu) and euthymic (nul+) BALB/c mice to investigate the role of T cells in immunity. It has been previously shown that the nulnu mouse is much more susceptible to infection than the nul+ mouse (18) . In our current model, the nulnu mouse can be protected by passive transfer of T lymphocytes (17) . Studies on lymphocyte subsets indicate that early in the infection, the CD4+ lymphocyte is the most important for transfer of protection (15) .
The goal of this study was to measure the production of CSFs during Chlamydia pneumonia and describe the cell types responsible for CSF production.
MATERIALS AND METHODS
Mice. Male and female specific-pathogen-free nul+ and nulnu mice from a BALB/c background were MoPn. The biovar MoPn of C. trachomatis was maintained in embryonated hen's eggs (17) . Mice were infected intranasally, after being anesthetized with sodium pentobarbital, with 102 to 105 inclusion forming units diluted in McCoy's modified SA medium in a volume of 0.05 ml. MoPn grown in eggs was heat-killed by incubation at 60°C for 60 min. Purified elementary bodies were prepared by Renografin density gradient centrifugation of cell culture-derived C. trachomatis (17) . The purified elementary bodies were killed under UV light before use as an antigenic stimulus. Quantitative culture of infected tissue was performed in McCoy cell monolayers and reported as inclusion forming units per organ (14) .
Supernatant production. At various times postinfection, mice were sacrificed and the spleens were removed aseptically. Single cell suspensions were prepared by grinding the spleens between the frosted ends of glass microscope slides. The spleen cells were washed and resuspended in RPMI 1640 supplemented with 5% fetal bovine serum (HyClone Laboratories, Logan, Utah), 100 ,ug of vancomycin per CSF assays. Plasma was collected at various times postinfection by cardiac puncture from Metofane-anesthetized mice. Plasma or supernatants were placed into 35-mm dishes with 105 bone marrow cells from C57BL/6J mice in McCoy 5A medium supplemented with penicillin (100 U/ml), streptomycin (100 ,ug/ml), amphotericin B (0.25 ,ug/ml), 15% fetal bovine serum, essential and nonessential amino acids, and 0.3% agar (6) . Cultures were incubated for 7 days at 37°C in 7.5% CO2. Colonies consisting of more than 50 cells were scored with a dissecting microscope. The amount of CSF activity (CSA) per ml was calculated by multiplying the number of colonies per plate by the inverse of the serum or supernatant dilution along the linear portion of the doseresponse curve (20) .
The growth-factor-dependent cell line FDCP-1 was also used to estimate CSA (8) . The FDCP-1 cell line proliferates in response to both IL-3 and GM-CSF. Samples were serially diluted in triplicate in 96-well microtiter plates. Afterward, 104 FDCP-1 cells were added to each well and the cultures were incubated for a total of 48 h. Tritiated thymidine (0.5 ,uCi per well) was added during the last 6 150 U/ml. By day 3, plasma CSA levels were significantly elevated and maximized at day 7. Thereafter, CSA declined, until basal levels were reached by day 28. To determine whether the induction of CSA required live organisms, nul+ mice were challenged with either live or heat-killed Chlamydia organisms, and plasma was harvested on days 7 and 14 postchallenge. Challenge with either live or heat-killed Chlamydia organisms induced increased CSA production on day 7 (2,800 ± 654 U of CSA per ml in nul+ mice challenged with live Chlamydia organisms versus 1,840 ± 706 U of CSA per ml in nul+ mice challenged with heat-killed organisms). However, by day 14, plasma CSA values in mice challenged with live organisms were significantly higher (1,680 ± 761 U of CSA per ml in mice challenged with live organisms versus 500 ± 120 U of CSA per ml in mice challenged with heat-killed organisms, P < 0.025). The maximum values of the latter experiment were higher than those of the former experiment, indicating some experiment-to-experiment variation in CSA values over the time course. Comparison of CSA production in nul+ and nulnu mice during infection. Plasma CSA levels in nul+ and nulnu mice were measured over the time course of infection (Fig. 2) . Plasma CSA values from uninfected (day 0) mice were 62 ± 36 U/ml. Maximum CSA was observed on day 3, followed by a slight decrease in activity on day 7. Thereafter, the serum CSA declined towards baseline levels, which were reached on day 28. In nulnu mice, the baseline CSA level was higher than in the nul+ mouse. The CSA levels were maximal on day 7 postinfection and declined on day 14 levels on any day during the time course (data not shown). In experiment 1, spleen cells from nu/+ mice did not produce significant CSA through day 1 postinfection. However, by day 3 postinfection, significant CSA levels were being secreted. Spleen cells maintained their ability to produce increased levels of CSA throughout the 30-day time course. In experiment 2, total CSA values from nulnu and nul+ mice were not significantly different during days 1 to 7 postinfection. Background levels were observed on day 1, with significant production occurring on day 3 for both nul+ and nulnu mice. The values from nulnu spleen cells declined and by day 14 were significantly lower than those from nul+ mice (P = 0.016). No other values were obtained from the nulnu mice since by day 16 all the athymic mice had succumbed to the infection, but CSA values from nul+ spleen cells remained elevated throughout the time course. In experiment 3, again both nul+ and nulnu mice produced high levels of CSA, with nulnu mice having significantly higher values on day 7 (P < 0.01). However, on day 14, values in nul+ mice were significantly higher than in nulnu mice (P < 0.001). The differences between maximum CSA values in experiments 2 and 3 indicate that there is some experiment-to-experiment variation in production. To determine the requirement for live organisms for spleen cell production, mice were challenged with live or heat-killed Chlamydia organisms, and spleen supernatants were harvested at days 7 and 14 postinfection. Like the serum, spleen cells from nul+ mice challenged with either live or heat-killed organisms produced CSA on day 7 (262 + 73 U of CSA per ml in mice challenged with live organisms versus 270 + 147 U of CSA per ml in mice challenged with heat-killed organisms). Yet by day 14, nul+ mice challenged with live organisms maintained the capacity to produce CSA (380 + 74 U of CSA per ml in nul+ mice challenged with live organisms versus 43 ± 17 U of CSA per ml in nul+ mice challenged with heat-killed organisms, P < 0.001). Additionally, nul+ mice produced significantly more CSA than nulnu mice challenged with either live or heat-killed Chlamydia organisms (380 ± 74 U of CSA per ml in nul+ mice challenged with live organisms versus 83 ± 20 U of CSA per ml in nulnu mice challenged with live organisms [P < 0.001] or versus 110 ± 67 U of CSA per ml in nulnu mice challenged with heat-killed organisms [P < 0.005]).
Effect of T-cell depletion of CSA production by nul+ spleen cells. The capacity of nul+ mice to maintain CSA production on day 14 indicated that an intact T-cell compartment may be required for some of the CSA production at that time. Therefore, we performed experiments in which spleen cells from infected nul+ mice were placed on day 14 into culture with MoPn antigen after depletion of T cells or T-cell subsets (Fig. 3) . In two separate experiments, total CSF secretion by spleen cells was 280 to 330 U/ml on this day. Treatment of spleen cells with anti-Thy 1.2 dramatically reduced the CSF secretion by immune spleen cells to 30 to 40 U/ml. Removal of CD4+, or helper T cells, also reduced the production of CSFs to 60 to 100 U/ml. In contrast, anti-CD8 treatment did not reduce the secretion of CSFs with concentrations of 370 to 460 U/ml. These studies show that in vitro CSA production by nul+ mice is strongly CD4+ on day 14. Production of IL-3 and GM-CSF by nul+ and nu/nu spleen cells. We next performed experiments using the growthfactor-dependent cell line FDCP-1 to confirm the presence of IL-3 and GM-CSF. Spleen cell supernatants were produced from nul+ and nulnu mice 7 and 14 days postinfection and assayed (Fig. 4) . Supernatants from nul+ mice supported significant growth of cells at 1:160 and 1:80 dilutions on days 7 and 14, respectively. Supernatants from nulnu mice supported significant growth only at a 1:20 dilution on both days. Therefore the nul+ mice produce four-to eightfold more GM-CSF and/or IL-3. Thus, nul+ mice are producing different types of CSFs from the nulnu mice. Since GM-CSF and IL-3 are produced by T cells, these results suggest that there may be a T-cell dependence of CSA production in nul+ mice.
DISCUSSION
In this article, we have shown for the first time that CSFs are produced in both nul+ and nulnu mice in vivo and in vitro in response to MoPn challenge. Early (day 7) responses, both in vivo and in vitro, could be induced with either live or heat-killed Chlamydia organisms. This is not surprising, since the capacity of killed organisms or subcellular bacterial fractions to induce changes in CSF production or other hematological responses has been documented with other models (4, 5, 22) . These early host responses, which we have shown in vitro with both nul+ and nulnu mice, are most likely independent of T-cell control and part of the natural host defense mechanisms. Yet, high late (day 14) responses were sustained only by live organisms in nul+ mice, indicating that induction of specific immunity may play a role in this phase of the response. This was confirmed by demonstrating that the in vitro CSF production on day 14 is strongly T-cell dependent, with the CD4+ cells being the most important subset.
The facts that significant amounts of CSFs are produced in vivo and in vitro by T-cell-deficient nulnu mice and that CD4+ dependent CSFs are produced in vitro on day 14 in nul+ mice suggest that more than a single type of CSF is produced in response to MoPn. This was confirmed by using the factor-dependent cell line FDCP-1. Supernatants from nul+ mice support the growth of FDCP-1 cells four-to eightfold better than the nulnu supernatants on both day 7 and day 14 and IL-3. IL-3 is produced exclusively by T cells, whereas GM-CSF is produced by T cells, macrophages, fibroblasts, and endothelial cells (9, 10) . These other cellular sources of GM-CSF may contribute to the early production of CSF levels in both nul+ and nulnu mice. Thus, the small amount of FDCP-1 activity in the nulnu supernatants may result from the production of GM-CSF by these alternative sources. Although increased total supernatant CSA in nul+ versus nulnu mice is apparent only on day 14 (Table 1) , the lack of obvious T-cell dependence in total CSA on day 7 may suggest a compensatory production of T-cell-independent CSA by nu/nu mouse spleens at that time. This concept may be supported by the significantly higher CSA levels in nulnu mice on day 7 in experiment 3 (Table 1) , which clearly represent high production of a non-T-cell-dependent factor in these mice. It is tempting to speculate that granulocyte CSF (a non-T-cell-dependent cytokine) is produced during infection by both nul+ and nulnu mice and may be the dominant CSF in the serum early in infection. Subsequently, GM-CSF and/or IL-3 are produced by primarily T-celldependent mechanisms in nul/+ mice by spleen cells. Further studies with our model will be needed to characterize the types of CSFs produced at different times in the various host compartments (plasma, spleen, and lung).
Our earlier published data on the histology of the inflammatory response in nul+ and nulnu mouse lungs suggests that cytokine production in the lung may mimic that observed in the spleen in these studies (3). The early pulmonary cellular response to infection in both types of mice is primarily the granulocyte. Although the Chlamydia organisms were found primarily in the type 1 epithelial cells, granulocytes containing intracellular organisms were seen by 10 h postinfection in both nulnu and nul+ mice. By day 14, the infiltrate in the nul+ mouse lung changed to predominantly mononuclear cells, yet in the nulnu mouse, the infiltrate was still primarily granulocytes. Challenge of Chlamydia-immune nul+ mice showed a different pattern of cellular reaction. The primary responding cell was the macrophage, and by 24 h, no organisms could be detected by electron microscopy. Thus, the in vivo difference in the phagocyte response between nul+ and nulnu mice suggest that different CSFs are being produced during infection in the lung and in the spleen.
T cells may have multiple roles in the anti-Chlamydia response. It has been found that the nulnu mouse is more susceptible than the nul+ mouse (17, 18) . Passive transfer studies have shown that T cells were the primary cells responsible for the transfer of protection. Furthermore, the CD4+ subset was the major contributor to protection (15) . One proposed mechanism for the role of CD4+ T cells could be the production of gamma interferon (IFN--y) . Previous studies from our and other laboratories indicate that removing IFN-y in vivo by injecting a monoclonal anti-IFN--y antibody renders mice more susceptible to chlamydial infection (14, 24) . Furthermore, by using another Chlamydia serovar, others have shown that treatment of mice with recombinant murine IFN--y reduces the number of organisms in the lungs, livers, and spleens (23) . Additionally, we and others have shown that IFN-y can inhibit the intracellular replication of chlamydiae in vitro (1, 12) . Thus, IFN--y is clearly one important cytokine in the immune response to MoPn.
Other cytokines have been shown to participate in host defenses. Recently, we have shown that T-cell clones against Listeria monocytogenes produce GM-CSF in addition to IFN-y (7, 8) . Supernatants from these clones were able to protect mice against lethal Listeria infection. By removing GM-CSF from these supernatants, protection was significantly diminished. Furthermore, immunotherapy with recombinant murine GM-CSF provided protection against Listeria monocytogenes.
Thus, host defenses against infectious challenge are clearly multifactorial. We believe that ultimate protective immunity against Chlamydia organisms results from the stimulation of T cells. The production of IFN--y is probably one important mediator of cellular immunity. The studies reported here show that the largely T-cell-derived CSFs (IL-3 and/or GM-CSF) are also produced in response to Chlamydia infection. The role of these factors in host resistance remains to be defined.
